Long-Term Molecular and Cytogenetic Response and Survival Outcomes With Imatinib 400 Mg, Imatinib 800 Mg, Dasatinib, and Nilotinib in Patients With Chronic-Phase Chronic Myeloid Leukaemia: Retrospective Analysis of Patient Data From Five Clinical Trials
The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(15)00021-6
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 1, 2015
Authors
Publisher
Elsevier BV